Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Savic

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|June 16, 2007
Diagnosing model diagnosticsM O Karlsson, R M Savic
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2021
Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant TuberculosisMarjorie Z Imperial, Jerry R Nedelman, Francesca Conradie, et al.
Clinical and Translational Science|February 5, 2017
Importance of Drug Pharmacokinetics at the Site of ActionM L Rizk, L Zou, R M Savic, et al.
BMC Infectious Diseases|December 9, 2022
A comparison of clinical development pathways to advance tuberculosis regimen developmentV Chang, P P J Phillips, M Z Imperial, et al.
Trials|August 4, 2021
A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trialsN K Hills, J Lyimo, P Nahid, et al.
Clinical and Translational Science|June 1, 2017
New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment ResponseI H Bartelink, N Zhang, R J Keizer, et al.
Clinical Pharmacology and Therapeutics|October 4, 2012
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patientsR M Savic, A Barrail-Tran, X Duval, et al.
Clinical Pharmacology and Therapeutics|August 12, 2015
Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for childrenR M Savic, R Ruslami, J E Hibma, et al.
Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.
Clinical Pharmacology and Therapeutics|July 15, 2016
A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on MetforminS Goswami, S W Yee, F Xu, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|June 16, 2007
Diagnosing model diagnosticsM O Karlsson, R M Savic
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2021
Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant TuberculosisMarjorie Z Imperial, Jerry R Nedelman, Francesca Conradie, et al.
Clinical and Translational Science|February 5, 2017
Importance of Drug Pharmacokinetics at the Site of ActionM L Rizk, L Zou, R M Savic, et al.
BMC Infectious Diseases|December 9, 2022
A comparison of clinical development pathways to advance tuberculosis regimen developmentV Chang, P P J Phillips, M Z Imperial, et al.
Trials|August 4, 2021
A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trialsN K Hills, J Lyimo, P Nahid, et al.
Clinical and Translational Science|June 1, 2017
New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment ResponseI H Bartelink, N Zhang, R J Keizer, et al.
Clinical Pharmacology and Therapeutics|October 4, 2012
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patientsR M Savic, A Barrail-Tran, X Duval, et al.
Clinical Pharmacology and Therapeutics|August 12, 2015
Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for childrenR M Savic, R Ruslami, J E Hibma, et al.
Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.
Clinical Pharmacology and Therapeutics|July 15, 2016
A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on MetforminS Goswami, S W Yee, F Xu, et al.
Pageof 2